This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We are writing in regard to the article by Vargas et al¹ entitled "A Pilot Study Evaluating the Treatment of Postparotidectomy Sialoceles with Botulinum Toxin Type A [BoNT/A]," which was published in the March 2000 issue of the ARCHIVES. In accordance with the experience of Vargas and colleagues, my coworkers and I recently reported our results using BoNT/F to treat a parotid sialocele.² Therefore, we believe that BoNT serotypes other than type A should be considered for use in patients who do not respond to treatment with BoNT/A. In 1995, Drobik and Laskawi³ suggested using BoNT/A to treat patients affected by gustatory sweating, or Frey syndrome. The goal was the reduction of facial sweating by the determination of a cholinergic autonomic block.

Different BoNT serotypes have been used to treat muscles of patients with immunoresistance to BoNT/A,^{4, 5, 6} but, to our knowledge, the use of BoNT serotypes other than BoNT/A has . . . [Full Text of this Article]